Shubhanshu Shukla shares BIG health update as astronaut learns to walk days after returning from space
In a video posted online, Shukla is seen taking assisted steps and later walking on a treadmill as part of his physical rehabilitation. 'I have received a lot of messages regarding my health and wishing me a speedy recovery,' he wrote in the caption. 'I want to thank you all and also give an update.'
Explaining the effects of space travel, Shukla noted that time in orbit impacts the body in several ways — from fluid redistribution and changes in heart rate to a temporary loss of balance and muscle strength. 'These are adaptations to the new environment,' he said. 'Once the body gets used to this and we return to gravity, these adjustments happen once again.'
He added that while recovery varies from person to person, the body is quick to respond. 'I was surprised to observe the pace with which our body can adjust to new settings,' he remarked.
According to Union Minister Jitendra Singh, Shukla and his three fellow crew members remain in quarantine until July 23, as per standard post-mission procedures. The isolation period allows doctors to monitor their condition and assist them in readapting to Earth's gravity.
Experts note that extended stays in space can result in weakened muscles, bone loss and coordination issues, making rehabilitation essential for a smooth return to everyday life.
Shukla's journey is being hailed as a milestone for India's space ambitions. During the mission, he completed over 310 orbits of Earth and covered a distance exceeding 13 million kilometres.
Shukla, along with three fellow astronauts, safely returned to Earth with a splashdown off the coast of California at 5:31 AM New York time on July 15. The mission marked a significant step for Texas-based company Axiom Space, which aims to collaborate with nations around the world to make space more accessible.
The crew had launched into orbit last month aboard a Falcon 9 rocket, which lifted off from NASA's Kennedy Space Center in Florida. They spent 18 days aboard the International Space Station (ISS) before heading back to Earth.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
21 minutes ago
- Business Standard
UK-India FTA to boost medical device trade amid country of origin concerns
Bilateral trade in pharmaceuticals and medical devices is set to receive a boost post the UK-India Free Trade Agreement (FTA), according to industry veterans. India's imports of medical devices from the UK grew by 36 percent to Rs 2,295 crore in FY24, while exports to the UK increased by 13 percent to Rs 1,015 crore. Rajiv Nath, Chairman and MD of Hindustan Syringes and Medical Devices (HMD)—one of the top three disposable syringe makers in the world—and the forum coordinator of the medical devices industry body Association of Indian Medical Device Industry (AiMeD), believes that bilateral trade will rise on both sides post the FTA. "Our top exports to the UK were contact lenses, diagnostic reagents, surgical instruments, and PPE kits, while our major imports were oxygen therapy equipment like ventilators, X-ray equipment, diagnostic testing reagents, and IVD analysis instruments. Mostly, small and mid-sized manufacturers export through distributors in niche markets," Nath said. 'Previously, medical devices imported into the UK were duty-free, so tariff restrictions were not an issue, but regulatory approval costs and time were a challenge. We sought recognition of Indian CDSCO regulatory approval or QCI's voluntary Indian certification for medical devices to fast-track regulatory approval by the UK MHRA and address non-tariff barriers faced by Indian exporters, and we look forward to an update on this,' Nath added. Regarding imports into India, AiMeD has emphasized the need for strict monitoring and verification of Rules of Origin to prevent misuse of the FTA through the potential routing of third-country products as purportedly UK-made goods. 'We welcome UK-made medical products into India via this FTA,' he added. Import duties levied by India were mostly at 7.5 percent, which, post-FTA, are expected to come down in a phased manner. The industry is, however, awaiting the fine print. As part of this agreement, import duties on MedTech products will be reduced from approximately 15 percent to around 3 percent, significantly lowering costs and improving access to advanced medical technologies, said Pavan Choudary, Chairman of the Medical Technology Association of India (MTaI). For pharmaceutical exports, the UK is already an important and growing market. Companies like Torrent Pharmaceuticals, Dr Reddy's Laboratories, and Aurobindo have a presence in the UK. 'With India's pharmaceutical exports to the UK reaching $914 million in FY24, the agreement strengthens supply chains, enhances access to affordable medicines, and drives Foreign Direct Investment (FDI). This partnership paves the way for collaborations in bulk drug imports, CDMO, and joint research, empowering India's competitive edge and promoting global partnerships,' said Namit Joshi, Chairman of the Pharmaceutical Exports Promotion Council. Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, noted that the pharma sector will have opportunities to supply affordable and quality-assured medicine, contributing to better patient care in the UK. 'We are awaiting further details to identify specific areas where these opportunities can be effectively leveraged,' Jain said.
Time of India
34 minutes ago
- Time of India
Torrent launches nutrition supplement powder for adults
Mumbai: Ahmedabad-based Torrent Pharmaceuticals has launched a nutrition supplement powder for adults to boost consumer-focused nutrition portfolio. The nutritional supplement is branded as Shelcal Total , a brand name acquired by Torrent Pharma in 2013, and was used to market gummies for adults and kids. Shelcal Total is a daily supplement designed to deliver targeted nutrients including calcium, magnesium, vitamin D3 and K2 for bone strength , and has glucosamine and bamboo shoot extract for joint health, the company said in a release. As per the company, of India's total $42.97 billion (around ₹3.57 lakh crore) nutrition supplements market powdered supplements account for nearly 38 per cent of the total share and with their bioavailability and ease of daily integration the segment stands as high-growth category going forward. 'With increase in health awareness, more adults are in need of convenient holistic nutrition, the demand for trusted, convenient solutions is only accelerating,' said Amal Kelshikar Chief Commercial Officer, India Business, Torrent Pharma.
News18
an hour ago
- News18
ADIA seeks CCI nod to acquire minority stake in Micro Life Sciences
New Delhi, Jul 24 (PTI) Abu Dhabi's sovereign wealth fund ADIA has sought approval from the Competition Commission of India (CCI) to acquire a 3 per cent stake in medical devices firm Micro Life Sciences Pvt Ltd (Meril) in a USD 200 million deal. The development came after a wholly-owned subsidiary of Abu Dhabi Investment Authority (ADIA) on Monday said it has entered into definitive agreements to invest USD 200 million for a 3 per cent stake in Meril. ADIA, through its affiliate Platinum Jasmine A 2018 Trust (acting through its trustee Platinum Owl C 2018 RSC Ltd), is acquiring a stake in Gujarat-based Meril. 'The acquirer (Platinum Jasmine A 2018 Trust) proposes to subscribe to certain equity shares proposed to be issued by the target (Micro Life Sciences) and acquire certain equity shares of the target from Bilakhia Holdings Pvt Ltd, amounting to approximately 3.06 per cent shareholding in the target," according to a notice filed with the CCI on Wednesday. Platinum Jasmine A 2018, Trust and Micro Life Sciences said the proposed transaction does not have any impact on any relevant market in India, let alone any appreciable adverse effect on competition, and therefore, the definition of the relevant product and geographic market may ultimately be left open. Following the transaction, ADIA said this investment values the firm (MERIL) at an enterprise value of USD 6.6 billion. Founded by the Bilakhia Group, Meril is a global innovator in medical technology with a focus on clinically advanced solutions across multiple specialities, including cardiovascular, structural heart, orthopaedics, endo-surgery, in-vitro diagnostics and surgical robotics. Headquartered in Vapi, Gujarat, Meril employs more than 13,000 people, has over 35 global subsidiaries, and serves healthcare systems in around 150 countries. 'This investment will enable us to accelerate growth, attract world-class talent, and further strengthen our…clinical research efforts as we work towards improving the quality of human life through advanced healthcare solutions," Sanjeev Bhatt, Senior Vice President – Strategy at Meril, said. Established in 1976, ADIA is a globally diversified investment institution that prudently invests funds on behalf of the Abu Dhabi government through a strategy focused on long-term value creation. PTI HG HG BAL BAL view comments First Published: July 24, 2025, 21:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
